In two placebo-controlled studies (total n=522) in HBeAg positive or in HBeAg negative chronic hepatitis B patients with compensated liver disease, significantly more patients (p < 0.001) in the 10 mg adefovir dipivoxil groups (53 and 64%, 8 respectively) had histological improvement from baseline at week 48 than in the placebo groups (25 and 33%).